ライフサイエンスコーパス: overall survival

1 t predictor of progression free survival and overall survival.

2 xic signaling within CTCs predicts decreased overall survival.

3 01) and TLG (p < 0.001) were associated with overall survival.

4 traits: condition, reproductive success and overall survival.

5 ncer prognosis modeling and into lung cancer overall survival.

6 ive care unit, length of oxygen support, and overall survival.

7 survival, relapse, nonrelapse mortality, or overall survival.

8 BMDex improved hematologic response rate and overall survival.

9 eatment arm for progression-free survival or overall survival.

10 tin mRNA levels display longer 3- and 5-year overall survival.

11 egies have facilitated major improvements in overall survival.

12 including acute intestinal GVHD and reduced overall survival.

13 highly significant independent predictor of overall survival.

14 ung patients face a poor quality of life and overall survival.

15 response, which, in turn, is associated with overall survival.

16 tatic pattern, metastasis-free survival, and overall survival.

17 in the stromal compartment, predicts reduced overall survival.

18 Primary endpoint was 5-year overall survival.

19 it disease progression and enhance patients' overall survival.

20 quired next treatment, transplant rates, and overall survival.

21 The primary outcome was 5-year overall survival.

22 terogeneous hematologic malignancy with poor overall survival.

23 e event-free survival, overall response, and overall survival.

24 rank methods were used to test prediction of overall survival.

25 of the Y chromosome or linc-SPRY3-2/3/4 and overall survival.

26 ere conducted to assess the effect of LRT on overall survival.

27 smic BOP1 was also inversely associated with overall survival.

28 geneity, pathway alterations, histology, and overall survival.

29 nd FGFR4-repressed signatures each predicted overall survival.

30 ction margin is most important in predicting overall survival.

31 return on investment with regards to 5-year overall survival (5Y-OS) compared with breast, prostate,

32 %, 13.5%, and 16.4%; P < 0.001) and superior overall survival (92%, 84%, and 75% vs 90%, 78%, and 68%

33 HR, 1.83; 95% CI, 1.15 to 2.92; P < .01) and overall survival (adjHR, 2.04; 95% CI, 1.22 to 3.40; P <

34 n progression-free survival (PFS) and median overall survival after BTKi initiation were 34 months (r

35 alysis of prognostic factors associated with overall survival after DEB-TACE, stressing the role of p

36 ugs have not proven to significantly improve overall survival after out-of-hospital cardiac arrest fr

37 le consumption may be associated with better overall survival among breast cancer patients, while hig

38 y markedly prolonged event-free survival and overall survival among children and adolescents with hig

39 to study the causal pathway from smoking to overall survival among lung cancer patients potentially

40 The primary outcome was 3-year overall survival, analysed by use of flexible proportion

41 Overall survival analyses were based on the intention-to

42 ogression-free survival analysis and interim overall survival analysis (May 31, 2019), median progres

43 on of 203 participants, our final cohort for overall survival analysis comprised 129 (64%) participan

44 quired number of events to trigger the final overall survival analysis had not been reached.

45 In the exploratory overall survival analysis in patients with PD-L1 immune

46 safety results from a prespecified, interim, overall survival analysis of ALCYONE with more than 36 m

47 database lock (March 21, 2018) for the final overall survival analysis, median follow-up was 7.4 mont

48 ere previously reported at the first interim overall survival analysis.

49 after approximately 240 deaths had occurred, overall survival and all other secondary end points were

50 r levels of KRCC1 which correlates with poor overall survival and chemoresistance.

51 albumin SPECT/CT was associated with better overall survival and disease control in hepatocellular c

52 e found that HUNK expression correlates with overall survival and distant metastasis free survival.

53 The coprimary endpoints were overall survival and imaging-based progression-free surv

54 Associations between margins and overall survival and local recurrence free survival were

55 Secondary endpoints were overall survival and objective response rate.

56 In this subset, the 1-year overall survival and progression-free survival (PFS) pro

57 The primary endpoints (overall survival and progression-free survival) have bee

58 rmed to investigate the associations between overall survival and r (voxelwise), maximum or median nS

59 Secondary end points included overall survival and safety.

60 Overall survival and toxic effects were also assessed.

61 analysed within this report include safety, overall survival, and duration of response, in keeping w

62 rate at 32 weeks, progression-free survival, overall survival, and pharmacokinetic and pharmacodynami

63 e primary outcomes were event-free survival, overall survival, and the pattern of treatment failure.

64 PSMA PET-derived whole-body tumor volume for overall survival are poorly elucidated to date.

65 Secondary objectives included determining overall survival as well as treatment outcomes according

66 endpoints were progression-free survival and overall survival assessed in the PD-L1 CPS of 10 or more

67 Overall survival at 2 years was 44.9% in the tucatinib-c

68 The primary endpoint was rate of overall survival at 3 months (OS3).

69 Overall survival at 3 years was 11% (95% CI 1-39) for pa

70 a median follow-up of 44 months (IQR 20-61), overall survival at 5 years was 54% (95% CI 44-63) in pa

71 omosome 9 gain) and a superior outcome (100% overall survival at 69 months), which was validated in a

72 Overall survival at 90 days was significantly improved i

73 atients with metastatic cancer have extended overall survival because of advanced therapies.

74 tention-to-treat analysis, the ICD group had overall survival benefit versus placebo drug (hazard rat

75 g, found no significant difference in 1-year overall survival between recipients of NMP versus COLD l

76 There was no difference in overall survival between SALV and NCRS (HR: 1.00, 95% CI

77 s no statistically significant difference in overall survival between the treatment groups (HR: 0.87,

78 Clinical data show significantly different overall survival between these clusters, and pathway ana

79 trial, standard dose of epinephrine improved overall survival but not neurologic outcomes in out-of-h

80 lant has been associated with recurrence and overall survival, but has not been evaluated in a large,

81 I colon cancer was not confirmed in terms of overall survival, but the absolute 0.4% difference in 5-

82 The coprimary endpoints were overall survival compared between the durvalumab monothe

83 ith lower 90-day mortality and better 3-year overall survival compared to ER, especially in patients

84 85 single-agent treatment did improve median overall survival compared to placebo (p = 0.04, n = 21)

85 f acute GVHD, thus translating into superior overall survival compared with historical results.

86 ntional PVP images had significantly shorter overall survival compared with those with low delta tumo

87 riods of disease-free survival and increased overall survival, compared with chemotherapy.

88 or-assessed progression-free survival at the overall survival database lock, median progression-free

89 However, median overall survival did not differ between the patients who

90 60.5], p=0.013), but event-free survival and overall survival did not differ between these two groups

91 rmed to investigate the impact of leakage on overall survival, disease-free survival, local and dista

92 I, 1.7-5.2]; p = 0.002), and a longer median overall survival duration (7.3 months [95% CI, 4.8-9.8]

93 his decline correlated with improved PFS and overall survival, especially when combined with CA19-9 d

94 Overall survival estimate at 6 months was 51.0%.

95 Collectively, the 5-year overall survival estimate of the 16 062 patients in the

96 Key secondary endpoints were overall survival, event-free survival, and progression-f

97 sponse relationship and its association with overall survival for (166)Ho radioembolization in patien

98 Median follow-up for overall survival for all 344 patients who had leukaphere

99 ys, the 1-year progression-free survival and overall survival for all evaluable patients were 36% (95

100 The two primary endpoints were overall survival for durvalumab plus platinum-etoposide

101 io, 0.085) had significant associations with overall survival for only IDH(wt) gliomas.

102 1/2 pathway are associated with the shortest overall survival for patients after diagnosis of colorec

103 follow-up of 4.9 years (IQR 3.9-8.4), median overall survival for patients with myelodysplastic syndr

104 Median overall survival for RP2D treated evaluable population,

105 Four-year EFS and overall survival for the entire cohort were 37% (95% CI,

106 rvival, without a significant improvement in overall survival, for patients with platinum-refractory

107 Overall survival from time of relapse at 1, 2, and 4 yea

108 Overall survival from TRB was not improved as a result o

109 id Tumours 1.1 progression-free survival and overall survival (group A vs group C) and overall surviv

110 nd overall survival (group A vs group C) and overall survival (group B vs group C), which was to be f

111 The results of the final analysis of overall survival have not yet been reported.

112 Results from the final analysis of overall survival have not yet been reported.

113 D was significantly associated with improved overall survival (hazard ratio 0.53, P < 0.001).

114 ee survival (hazard ratio, 1.5; P = .02) and overall survival (hazard ratio, 1.7; P = .01).

115 -specific survival (HR = 0.65, p < 0.01) and overall survival (HR = 0.70, p < 0.01).

116 Overall survival (HR, 0.91 [95% CI, 0.54 to 1.53]) and D

117 e survival (HR: 0.93; 95% CI: 0.48, 1.79) or overall survival (HR: 0.91; 95% CI: 0.45, 1.85).

118 ional therapy; LRT) could be associated with overall survival improvements.

119 ned inhibition of BRAF and MEK has increased overall survival in advanced BRAF-mutant melanoma in bot

120 lated with relapse-free, metastasis-free, or overall survival in breast cancer.

121 The median overall survival in cohort A was 18.5 months in the olap

122 of TAM phenotypes as prognostic factors for overall survival in lung cancer.

123 hat S70pBcl2 is associated with lower median overall survival in lymphoma patients.

124 stuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastat

125 Overall survival in patients with relapsed disease remai

126 on final pathology, had inferior DFS but not overall survival in the entire cohort.

127 t chemotherapy did not significantly improve overall survival in those with no high-risk pathologic f

128 results showed a significantly worse 5-year overall-survival in HPSCC compared with LSCC before and

129 V expression was correlated with a shortened overall-survival in the patients' group that underwent p

130 al Cancer (MECC) study had information about overall survival instead of progression-free survival.

131 t this interim analysis; follow-up to assess overall survival is continuing.

132 aller clones (<5% VAF), which did not affect overall survival, larger clones were associated with inc

133 ne in PSA at 6 wk was associated with longer overall survival (median, 16.7 mo; 95% CI, 14.4-19.0) th

134 positive MRD had dismal progression-free and overall survivals (median, 14 and 17 months, respectivel

135 l to prevent or delay recurrence and prolong overall survival.METHODSTwenty-eight patients with prima

136 e (interaction test P = .0694) and an HR for overall survival of 0.42 versus 1.23 in basal phenotype

137 with recurrent disease (n = 4) had a median overall survival of 8.5 months.

138 ceiving palliative chemotherapy has a 5-year overall survival of about 10%.

139 es a correlation between CD82 expression and overall survival of AML patients.

140 l and biologic features, has improved 5-year overall survival of childhood acute lymphoblastic leukem

141 Importantly, recurrence-free and overall survival of colorectal cancer (CRC) patients neg

142 Compared with F-fit patients, the overall survival of F-unfit patients was significantly s

143 e incidence of lung metastasis and increased overall survival of mice when injected into mammary fat

144 sses and both negatively correlated with the overall survival of pancreatic cancer patients.

145 rgeted therapies are effective for improving overall survival of patients with advanced prostate canc

146 Furthermore, CHD4 was associated with poor overall survival of patients with breast cancer.

147 r-expressing natural killer and T cells, the overall survival of patients with PTCLs will dramaticall

148 ore-matched analysis was used to compare the overall survival of patients with stage IA NSCLC in the

149 oves the sensitivity of TMZ and enhances the overall survival of the respective tumor-bearing mice.

150 hway mutations were not associated with PFS, overall survival, or objective response after CPI.

151 ) mutations in PBRM1 are not associated with overall survival (OS) (HR = 1.24, p = 0.47) or time to t

152 FS) [hazard ratio (HR) 0.32, p < 0.001], and overall survival (OS) [HR 0.45, p = 0.01], and was an in

153 Median overall survival (OS) after MPE diagnosis was 9 months.

154 Overall survival (OS) and disease-free survival (DFS) we

155 Primary endpoints were overall survival (OS) and disease-specific survival (DSS

156 ree survival (DFS), secondary endpoints were overall survival (OS) and local control (LC).

157 Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy o

158 luding 2 postoperative deaths, 1- and 5-year overall survival (OS) and recurrence-free survival (RFS)

159 scriminative groups to improve prognosis for overall survival (OS) and relapse free survival (RFS) ou

160 ife, and progression-free survival (PFS) and overall survival (OS) at 1, 2, and 3 y.

161 Overall survival (OS) at 12 months was 40% (95% CI, 22%-

162 rolonged progression-free survival (PFS) and overall survival (OS) at PM (OS: hazard ratio [HR], 0.6

163 ysis was used to group patients with similar overall survival (OS) based on clinical T/N stage, tumor

164 e survival benefit did not translate into an overall survival (OS) benefit in randomized phase III tr

165 tion rates, radical (R0) resection rates and overall survival (OS) between the validation patients an

166 Overall survival (OS) differed significantly among ELN r

167 tment parameters was performed using PFS and overall survival (OS) end-points.

168 Primary end point was overall survival (OS) evaluated using adjusted Cox regre

169 fits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI

170 dysregulation of BLM is associated with poor overall survival (OS) for lung and gastric cancer patien

171 However, overall survival (OS) for TERT-low/non-ALT patients was

172 CTx and performed sensitivity analyses with overall survival (OS) from relapse and Kaplan-Meier stat

173 e survival from the second randomization and overall survival (OS) from the first or second randomiza

174 luence of TDT on remission, early death, and overall survival (OS) in univariable analyses for each d

175 ogression-free survival (PFS) of >= 9 mo and overall survival (OS) of >= 15 mo as reference.

176 ancer have a dismal prognosis, with a median overall survival (OS) of 12-14 months with systemic ther

177 th the clinicopathologic characteristics and overall survival (OS) of PDA patients.

178 The overall survival (OS) rates at 1-, 3-, and 5- years from

179 , 5-year progression-free survival (PFS) and overall survival (OS) rates were 72% and 84% for ITT, 85

180 The 7-year DFS and overall survival (OS) rates were not different as well,

181 The median overall survival (OS) time for the entire cohort was 126

182 nts were progression-free survival (PFS) and overall survival (OS) times.

183 Median overall survival (OS) was 18 months (95% CI, 8-27); 5-ye

184 survival (hemEFS) was 11.8 months and median overall survival (OS) was 25.6 months.

185 a median follow-up of 4.5 years, the 5-year overall survival (OS) was 91%.

186 rolled in AALL0331 was 88.96% +/- 0.46%, and overall survival (OS) was 95.54% +/- 0.31%.

187 l TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a

188 survival (DFS) was the primary endpoint, and overall survival (OS) was the secondary endpoint.

189 esults: Median progression-free survival and overall survival (OS) were 13.9 and 22.3 mo, respectivel

190 Three-year progression-free and overall survival (OS) were 57% and 71%, respectively (me

191 Associations between these parameters and overall survival (OS) were assessed with the Cox proport

192 Observed metastasis-free survival (MFS) and overall survival (OS) were estimated using the Kaplan-Me

193 Differences in progression-free (PFS) and overall survival (OS) were evaluated using log-rank test

194 Postoperative mortality and overall survival (OS) were similar between sexes.

195 Among them, eight studies provided data on overall survival (OS) with a pooled HR of 1.91 (95% CI:

196 d to assess, through a metaanalysis, whether overall survival (OS) with SIRT, as monotherapy or follo

197 ival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison bet

198 and SF, 5-year event-free survival (EFS) and overall survival (OS), and treatment-related mortality (

199 inferior progression-free survival (PFS) or overall survival (OS), apart from inferior OS for patien

200 points were disease-free survival (DFS) and overall survival (OS), estimated using the Kaplan-Meier

201 Secondary end points included overall survival (OS), intracranial progression-free sur

202 view (BICR); additional assessments included overall survival (OS), overall response rate (ORR), dura

203 Clinicopathologic characteristics, overall survival (OS), recurrence-free survival (RFS), a

204 Long-term outcomes, including overall survival (OS), recurrence-free survival (RFS), d

205 screening design with a primary end point of overall survival (OS), using an alpha of .20 (wherein P

206 ver, these parameters were not predictive of overall survival (OS), which highlighted the challenges

207 utcomes were disease free survival (DFS) and overall survival (OS).

208 dictive of recurrence-free survival (RFS) or overall survival (OS).

209 (DOR), progression-free survival (PFS), and overall survival (OS).

210 eir change at treatment discontinuation with overall survival (OS).

211 atients' progression-free survival (PFS) and overall survival (OS).

212 5-year disease-specific survival (DSS), and overall survival (OS).

213 ints were toxicity and predictors of EFS and overall survival (OS).

214 mine which scoring system best discriminates overall survival (OS).

215 atment, progression-free survival (PFS), and overall survival (OS).

216 d log-rank test was used to compare bRFS and overall survival (OS).

217 (LR), (iv) disease free survival (DFS), (v) overall survival (OS).

218 pattern, metastasis-free survival (MFS), and overall survival (OS).

219 ee survival (EFS) +/- SE (0.40 +/- 0.01) and overall survival (OS; 0.45 +/- 0.02) were significantly

220 nths, chi2 p = 0.001) and 15 fewer months of overall survival (OS; 95% CI -1 to 31, 92-120 versus 113

221 (primary end point) and event-free (EFS) and overall survival (OS; secondary end points) were compare

222 lted in better progression-free survival and overall survival outcomes than adding placebo; the risks

223 Risk group predicted event-free survival and overall survival (p<0.0001).

224 Pneumonia did not impact on overall survival (P=0.807).

225 ion, overall clinicohaematological response, overall survival, patient-reported outcomes, and safety

226 IGFBP-5 expression had significantly shorter overall survival periods than those with low expression

227 Overall survival probability after percutaneous cryoabla

228 The overall survival rate after extracorporeal cardiopulmona

229 The 5-year overall survival rate for all patients was 87%.

230 s are consistently disappointing with 5-year overall survival rates of ~10%.

231 tio 0.69, 95% CI 0.58-0.82); 8-year landmark overall survival rates were 37% (95% CI 31-42) in the pe

232 nt-free survival, relapse-free survival, and overall survival rates were 67.7% (95% CI, 55.9% to 79.4

233 The 5-year event-free and overall survival rates were 83.7% +/- 1.1% and 89.5% +/-

234 The estimated 5-year event-free and overall survival rates were 92.0% +/- 3.9% and 96.0% +/-

235 The overall survival rates were significantly higher in the

236 gnificant independent prognostic factors for overall survival (Relative Risk: 2.129, p < 0.0001) and

237 ied within 6 months of diagnosis, but 3-year overall survival remained low in women who survived to t

238 Liver transplantation provides the longest overall survival reported in colorectal cancer patient w

239 Here, we report the secondary endpoint of overall survival results for the RANGE trial.

240 ression-free survival (rwPFS) and real-world overall survival (rwOS) from the time of 2 L treatment i

241 , but the absolute 0.4% difference in 5-year overall survival should be placed in clinical context.

242 eprivation therapy resulted in longer median overall survival than placebo plus androgen-deprivation

243 parib had a significantly longer duration of overall survival than those who were assigned to receive

244 sponse rates and longer progression-free and overall survival than those with NMRs <5.75.

245 nked miRNAs are significantly related to the overall survival time in the breast and liver cancers gr

246 nt with the statistically significant longer overall survival times of DIPG patients harboring ACVR1

247 ry patients, the median progression-free and overall survival times were not yet reached, with only 1

248 sthoracic and transhiatal procedures (5-year overall survival: transthoracic MIE 49.2% vs. OE 51.1%,

249 e target was observed, resulting in enhanced overall survival tumor regression up to 50% in the treat

250 ne and directly compare modeling lung cancer overall survival using gene expressions versus histopath

251 um-etoposide showed sustained improvement in overall survival versus platinum-etoposide (HR 0.75 [95%

252 Median overall survival was 12.3 months for cisplatin plus FU (

253 95% CI 0.62-0.91]; nominal p=0.0032); median overall survival was 12.9 months (95% CI 11.3-14.7) vers

254 At a median follow-up of 31.4 mo, median overall survival was 13.3 mo (95% CI, 10.5-18.7 mo), wit

255 In cohort B, the median duration of overall survival was 14.1 months with olaparib and 11.5

256 In the high PD-L1 population, median overall survival was 14.4 months (95% CI 10.4-17.3) in t

257 In the intention-to-treat population, median overall survival was 15.1 months (13.1-18.0) in the durv

258 Median overall survival was 16.9 months (95% CI 1.5-32.3), and

259 The median overall survival was 18.2 months (95% CI, 11.3 to 43.8 m

260 was 5.5 months (95% CI 3.4-5.9), and median overall survival was 19.0 months (11.0-not estimable).

261 CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respec

262 h PD-L1 immune cell-positive tumours, median overall survival was 25.0 months (95% CI 19.6-30.7) with

263 vival was 17 mo (range, 0-30 mo), and median overall survival was 32 mo (range, 4-53 mo).

264 3-year overall survival was 50% (95% CI 48-53), but we observed

265 Median overall survival was 57.1 months (95% CI 50-72) in the p

266 nts versus all TERTp-wt patients, the median overall survival was 58 months and 160 months, respectiv

267 4-year overall survival was 68% (58-81); 74% (60-91) in adolesc

268 The overall survival was 70%/59%/52%, at 1-/3-/5-years, resp

269 d 88% power needed for significance), 4-year overall survival was 77.9% (95% CI 73.7-81.5) with nivol

270 Median overall survival was 8.2 months with ATRA v 5.1 months w

271 Overall survival was 83.3% (95% confidence interval [CI]

272 At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 8

273 ree survival by investigator assessment, and overall survival was a key secondary endpoint.

274 ent response, progression-free survival, and overall survival was also determined.

275 Overall survival was assessed with a group sequential te

276 Overall survival was best in the immune-activated group.

277 Overall survival was calculated using the Kaplan-Meier m

278 Overall survival was not analyzed, since the required nu

279 Median overall survival was not reached (95% CI, 10.7 months to

280 Median overall survival was not reached at the median follow-up

281 hs (IQR 37.4-43.1), a significant benefit in overall survival was observed for the D-VMP group.

282 C), which was to be formally tested only if overall survival was positive for group A versus group C

283 Overall survival was significantly different between pat

284 hs, the 1-year progression-free survival and overall survival were 23% and 56%, respectively.

285 dian follow-up of 70 months, rates of 5-year overall survival were 54% in the laparoscopic group and

286 Associations with post-HSCT overall survival were as follows: HR 1.24, 95% CI 1.02-1

287 were significantly different with respect to overall survival were bilirubin levels (p<0.001), pretre

288 astasis-free survival (cMFS) and conditional overall survival were calculated based on the observed M

289 and the capability of each method to predict overall survival were evaluated.

290 The data for the analysis of overall survival were immature at the time of the primar

291 and subsequent reports, progression-free and overall survival were significantly improved in the pert

292 IQR 4.9-7.9), 5-year event-free survival and overall survival were: 88.9% (95% CI 84.0-93.8) and 96.2

293 ing animals and further increased median and overall survival when combined with anti-PD-1.

294 atment decreases in pIL-8 exhibited improved overall survival when treated with atezolizumab but not

295 ic time, oxygenation, ICU length of stay, or overall survival when used in the peri-intubation period

296 The primary outcome was overall survival, which was evaluated using Kaplan-Meier

297 Conclusion The target median overall survival with CT-guided percutaneous irreversibl

298 Overall survival with endotherapy was 73% at 5 years and

299 Comorbidity score analysis showed decreasing overall survival with increasing comorbidity index.

300 R], 2.47; 95% CI, 1.30 to 4.71) and improved overall survival, with a 2-fold decrease in mortality ra